We are aiming to formulate the busulfan injection, bendamustine HCL injection and tacrolimus injection without organic solvent. The formulation's strength will be comparable to formulations currently on the market. The chosen drugs are in the high demand with substantial market share. For instance, U.S. sales for busulfan injection; were approximately $97 million for the 12 months ending Sept. 30, 2017, according to IQVIA.23 Around $300 million is made annually from bendamustine sales. This is only the reference example of one region, i.e., US, the worldwide sales are obviously higher. Between the years 2022 and 2030, it is anticipated that sales of tacrolimus will total more than three thousand million dollars across the globe. After completion of the successful research, we have planned to make contract with pharmaceutical industries (currently under discussion) to find a way towards commercialization of promising molecules. Many industries are interested in alternative anticancer and immunosuppressant formulations without the use of toxic organic solvents. Also, it would be the great move for society if we could develop formulations without toxic solvents and with minimum side effects.

2023